What’s new in 2026?
Published on 13 November 2026, WHO’s first dedicated guideline on type 1 diabetes in children and adolescents up to 19 years of age brings early recognition, insulin treatment, emergency care and long-term surveillance into a single resource for primary and secondary care. It also addresses decisions in settings with limited access to laboratory tests, insulin analogues and glucose monitoring technology.
| Clinical decision | What WHO recommends in 2026 |
|---|---|
| Suspected diabetes when blood glucose testing is unavailable | Use a urine dipstick for glucose and/or ketones to support initial assessment. In a stable child, confirm blood glucose before starting treatment. |
| Possible DKA in children under five | Evaluate for diabetes and DKA if symptoms suggest DKA or there are other signs of serious illness. Use a urine dipstick if blood glucose testing is unavailable. |
| Choosing insulin | Use basal and mealtime insulin where feasible. WHO conditionally favours regular human insulin for mealtime coverage, with cost and access informing the preference. NPH and long-acting analogues are both basal options. |
| Setting a glycaemic target | Aim for HbA1c 6.5–7.2% (48–55 mmol/mol) where safely achievable. WHO suggests capillary glucose checks at least four times daily, tailored to the child’s circumstances. |
| Starting complication screening | Start eye screening at age 11 or five years after diagnosis and kidney screening at age 11 or two years after diagnosis. Use the earlier milestone in each case. |
The recommendation to evaluate seriously ill children under five for possible DKA is strong. The insulin, glycaemic target and screening recommendations are conditional. Evidence certainty is high for the intensive glycaemic management recommendation and low or very low for several insulin, DKA and screening decisions.
1. Presentation and initial assessment
Think of type 1 diabetes in a child with polyuria, polydipsia, weight loss or fatigue. New bedwetting can be a clue in a previously dry child. Vomiting, abdominal pain, dehydration, deep or rapid breathing and drowsiness raise concern for diabetic ketoacidosis (DKA). In young children, DKA can resemble gastroenteritis or sepsis, so check glucose early in the assessment of a seriously ill child.
- Assess stability. Check perfusion, hydration, breathing and mental status. Suspected DKA or shock warrants urgent assessment in a setting equipped to manage paediatric DKA.
- Measure glucose promptly. If blood testing is unavailable, use a urine dipstick for glucose and ketones. Both together raise concern for DKA. Stress hyperglycaemia can cause isolated glycosuria, and fasting or reduced intake can cause isolated ketonuria.
- Act on the clinical findings. Confirm hyperglycaemia with point-of-care or laboratory blood glucose before starting treatment in a stable child. In a seriously ill child with suspected DKA, begin supportive care and arrange escalation while pursuing biochemical confirmation.
2. Confirming suspected DKA
Assess hyperglycaemia, metabolic acidosis and ketosis together. In a symptomatic child, start with point-of-care glucose and ketone testing where available, then obtain a venous blood gas and electrolytes.
| Component | Thresholds cited by WHO for suspected DKA |
|---|---|
| Hyperglycaemia | Blood glucose ≥11.1 mmol/L (200 mg/dL) |
| Metabolic acidosis | Venous pH <7.30 and/or serum bicarbonate <15 mmol/L |
| Ketosis | Blood β-hydroxybutyrate >3 mmol/L and/or urine ketones ≥2+ |
With typical symptoms and bicarbonate 15–18 mmol/L, WHO advises keeping DKA in the differential and proceeding with appropriate testing and management. Interpret results in context, particularly when sepsis, severe dehydration or renal impairment could explain some of the abnormalities.
3. Acute management of DKA
Assess perfusion → start fluids → begin insulin after the first hour of IV fluids → reassess glucose, electrolytes and neurological status throughout treatment.
| Step | Clinical approach |
|---|---|
| Initial fluids | In shock, start isotonic IV fluid. WHO’s remarks cite 10–20 mL/kg over 30–60 minutes as a possible range, with the volume and rate adjusted to response. Without shock, replace fluids cautiously and reassess hydration, perfusion and neurological status. |
| Ongoing rehydration | WHO suggests IV rehydration for at least 24 hours, with rate and duration tailored to response. An isotonic crystalloid may be used for maintenance. Consider sodium, osmolality, hydration, urine output and oral tolerance. |
| Insulin | Start after the first hour of IV fluids. WHO allows regular human insulin or a rapid-acting analogue by continuous IV infusion or intermittent subcutaneous injection according to context. Its remarks give 0.05–0.1 units/kg/hour IV or 0.15–0.2 units/kg subcutaneously every two hours. IV insulin boluses are generally unnecessary. |
| Monitoring and escalation | Follow glucose, potassium, urine output, perfusion and neurological status closely. Guide potassium replacement by laboratory results where available. If testing is unavailable, WHO allows consideration of replacement after adequate urine output is confirmed. Escalate urgently if neurological status deteriorates. |
WHO’s DKA fluid and insulin recommendations are conditional and supported by low or very low certainty evidence. Use the local paediatric DKA protocol for prescribing, monitoring intervals, dextrose and electrolyte adjustments, and transition to subcutaneous insulin.
4. Building the long-term insulin regimen
Once the child is stable, use basal insulin for background needs and bolus insulin for meals. Choose a regimen the family can administer reliably with the insulin, supplies and support available to them.
- Starting dose. WHO suggests 0.5–1.0 IU/kg/day as the initial total daily dose, divided into basal and prandial components. Individualise for age, puberty, weight and metabolic status. Infants and children under five may need the lower end of the range. Reassess against glucose patterns and hypoglycaemia.
- Basal insulin. Either NPH or a long-acting analogue may be used. Account for dosing needs, hypoglycaemia, affordability and continuity of supply.
- Mealtime insulin. WHO conditionally favours regular human insulin over rapid-acting analogues. This reflects very low certainty comparative evidence and the importance of cost and equitable access.
- Delivery. Choose an insulin pen or vial and syringe based on the child’s needs, family preference, cost and availability. Ask the child or caregiver to demonstrate the technique.
5. Monitoring, hypoglycaemia and follow-up
Review daily glucose patterns alongside HbA1c. HbA1c reflects average glycaemia over the preceding two to three months. Glucose records show when lows and highs occur and help guide adjustment.
| At home | At follow-up |
|---|---|
| Link glucose checks to meals and bedtime. WHO suggests four or more checks daily, with more frequent checks during illness or insulin adjustment. Consider continuous glucose monitoring where feasible and affordable. | Review glucose records, hypoglycaemia, insulin technique, family workload and supply access. Quarterly HbA1c is common. Individualise the interval and consider extending it when glycaemia is stable. |
| Give the family a written plan for illness, hypoglycaemia and when to seek urgent help. Review how it will work at school and away from home. | Aim for HbA1c 6.5–7.2% if achievable without recurrent or severe hypoglycaemia, excessive treatment burden or harm to psychosocial well-being. Consider a less intensive target when hypoglycaemia risk is high or monitoring and support are limited. |
Treat suspected hypoglycaemia promptly if glucose testing is delayed or unavailable. Give oral glucose if the child is conscious, cooperative and can swallow safely. Use IV glucose if the child is unconscious or uncooperative. Glucagon is an alternative where available. Recurrent or severe episodes should prompt review of insulin doses, meal timing, activity and the family’s ability to recognise and treat a low.
6. Screening for eye and kidney complications
Record both the child’s age and diagnosis date so the care team can schedule screening at the earlier milestone.
| Complication | When to start | Follow-up |
|---|---|---|
| Diabetic retinopathy | Age 11 or five years after diagnosis, whichever comes first | Screen every two to five years according to risk. Five years may suit children consistently meeting intensive glycaemic targets. Two years is suggested for those missing targets, with more frequent assessment considered according to individual risk or established retinopathy. |
| Diabetic nephropathy | Age 11 or two years after diagnosis, whichever comes first | Urine albumin-to-creatinine ratio is one option. Tailor screening to glycaemic control, other risk indicators and family circumstances. Persistently elevated HbA1c above 9.0% (75 mmol/mol) is one marker of higher risk. |
Link screening to routine diabetes visits where possible. At each visit, check whether the family has enough insulin and monitoring supplies, can respond to hypoglycaemia and illness, and knows whom to contact between appointments.
